---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-267696"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:43:32.992452+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines sets final merger exchange ratio at 0.1112; ISS/Glass Lewis back deal

## Summary
- Final exchange ratio: 0.1112 RVMD shares per EQRx share, up from illustrative 0.0734.
- ISS and Glass Lewis recommend RVMD stockholders vote FOR the share issuance.
- Merger expected to add ~$1.1B net cash (~$20 per share issued); close targeted Nov 2023.
- RVMD to issue ~55M shares (excl. warrants/earn-outs) for the acquisition.
- RVMD special meeting of stockholders scheduled for November 8, 2023.

## SEC filing metadata
- accession: 0001193125-23-267696
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312523267696/0001193125-23-267696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312523267696/d527979d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-267696
- JSON: https://secwatch.observer/filing/0001193125-23-267696.json
- Plain text: https://secwatch.observer/filing/0001193125-23-267696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.